Titan Pharmaceuticals, Inc. (Nasdaq: TTNP) announced the planned presentation of data from four post hoc sensitivity analyses of the final ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine(R) for Opioid DependenceJune 15, 2016 7:00 AM Preliminary Russell 3000 Additions and DeletionsJune 13, 2016 11:53 AM Titan Pharma (TTNP) Receives Milestone Payment for FDA Approval of ProbuphineJune 13, 2016 7:03 AM Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R)June 13, 2016 7:00 AM